EE650 Incremental Costs of Tofacitinib Compared to Adalimumab and Ixekizumab for the Treatment of Active Ankylosing Spondylitis in Denmark

Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.915
https://www.valueinhealthjournal.com/article/S1098-3015(23)04045-7/fulltext
Section Title :
Section Order : 10403
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04045-7&doi=10.1016/j.jval.2023.09.915
HEOR Topics :
Tags :
Regions :